相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain
Rafael Canton et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
Florian Wagenlehner et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
Andrea Novelli et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Carbapenemase-Producing Gram-Negative Bacteria in Andalusia, Spain, 2014-2018
Inmaculada Lopez-Hernandez et al.
EMERGING INFECTIOUS DISEASES (2020)
In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
Christopher Longshaw et al.
JAC-ANTIMICROBIAL RESISTANCE (2020)
Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018
Alma Brolund et al.
EUROSURVEILLANCE (2019)
Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study
Sergio Garcia-Fernandez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A. Karlowsky et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
Akinobu Ito et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
Jeanne B. Forrester et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
Naoki Kohira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
Akinobu Ito et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Tsukasa Ito-Horiyama et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3
Jesus Oteo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from US Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The increasing threat of Pseudomonas aeruginosa high-risk clones
Antonio Oliver et al.
DRUG RESISTANCE UPDATES (2015)
A review on colistin nephrotoxicity
Atefeh Ordooei Javan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Abiola O. Olaitan et al.
FRONTIERS IN MICROBIOLOGY (2014)
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2012)
分享论文
